MODERN METHODS OF TREATING GOUT

Berdieva Rano Sultonovna; Shaimardanov Olim Igamuratovich; Khamraeva Gulchekhra Mamadullaevna; Suyunova Manzura Boymuradovna

MODERN METHODS OF TREATING GOUT

Berdieva Rano Sultonovna

Termez branch of the Tashkent Medical Academy Department of Internal Medicine, Military Field Therapy, Hematology and Family Medicine Therapy

Shaimardanov Olim Igamuratovich

Termez branch of the Tashkent Medical Academy Department of Internal Medicine, Military Field Therapy, Hematology and Family Medicine Therapy

Khamraeva Gulchekhra Mamadullaevna

Termez branch of the Tashkent Medical Academy department of internal medicine propaedeutics, rehabilitation, folk medicine, endocrinology

Suyunova Manzura Boymuradovna

Termez branch of the Tashkent Medical Academy department of internal medicine propaedeutics, rehabilitation, folk medicine, endocrinology

##semicolon## padagra, allopurinol, dose, research, therapy.

सार

Gout is a systemic tophi disease from the group of microcrystalline arthritis, which is characterized by the deposition of monosodium urate crystals in various tissues and the inflammation that develops in connection with this in individuals with hyperuricemia caused by environmental and/or genetic factors. Over the past decades, it has been considered one of the most studied and treatable rheumatic diseases, however, the frequency of errors made when prescribing therapy for patients with gout remains extremely high.

##submission.citations##

Елисеев М. С., Барскова В. Г. Влияние росиглитазона на показатели углеводного и уратного обмена у больных подагрой: Тез. докл. IV Всероссийского диабетологического конгресса. — М., 2008. — С. 102.

Ильина А. Е., Барскова В. Г. Применение урисана при подагре // Современная ревматология. — 2008. — № 1. — С. 81–83.

Кудаева Ф. М., Елисеев М. С., Барскова В. Г. и др. Сравнение скорости наступления анальгетического и противовоспалительного эффектов различных форм нимесулида и диклофенака натрия при подагрическом артрите // Тер. архив. — 2007. — № 5. — С. 35–40.

Насонова В. А., Барскова В. Г. Ранние диагностика и лечение подагры — научно обоснованное требование улучшения трудового и жизненного прогноза больных // Научно-практическая ревматология. — 2004. — № 1. — С. 5–7.

Allovay J. A., Moriarty M. J., Hoogland Y. T. et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis // J. Rheumatol., 1993; 20: 111–113.

De La Serna G., Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile and reduces uricaemia // Clin. Pharmacol. Ther., 1999; 66: 166–172.

Dessein P., Shipton E., Stanwix A. et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study // Ann. Rheum. Dis., 2000; 59: 539–543.

Eliseev M. S., Barskova V. G., Volkov A. V. et al. The efficacy and safety of metformin treatment in gouty patients with insulin resistence syndrome (pilot case control 6-months study) // Ann. Rheum. Dis., 2005; 64 (suppl. 3): 500.

Emmerson B. T. The management of gout // N. Engl. J. Med., 1996; 334: 445–451.

Feher M. D., Hepburn A. L., Hogarth M. B. et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout // Rheumatology, 2003; 42: 321–325.

Feher M. D., Caslake M., Foxton J. et al. Atherogenic lipoprotein phenotype in 2 diabetes: reversal with fenofibrate // Diabetes Metab. Res. Rev., 1999; 15: 395–399.

Fernandez C., Noguera R., Gonzalez J. A. et al. Treatment of acute attacks of gout with small doses of intraarticular triamcinolone acetonide // J. Rheumatol., 1999; 26: 2285–2286.

Groff G. D., Franck W. A., Raddatz D. A. Systemic steroid therapy for acute gout: a clinical trial and review of the literature // Seminars Arthritis Rheum., 1990; 19: 329–336.

Hollander J. L. Arthritis and Allied Conditions: A Textbook of Rheumatology. 6th ed. Philadelphia: Lea & Febiger, 1960.

Huang H. Y., Appel L. J., Choi M. J. et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a ra ndomized, controlled trial // Arthritis Rheum., 2005; 52: 1843–1847.

Iwatani M., Wasada T., Katsumori K. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and nondiabetic // Diabetologia, 2000; 43: 814–815.

Janssens H. J., Janssen M., van de Lisdonk E. H. et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial // Lancet, 2008; 371: 1854–1860.

Mikuls T. R., Farrar J. T., Bilker W. B. et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD) // Rheumatology (Oxford), 2005; 44: 1038–1042.

Morris I., Varughese G., Mattingly P. Colchicine in acute gout // BMJ, 2003; 327: 1275–1276.

Neogi T., Hunter D. J., Chasson C. E. et al. Frequency of inappropriate management of acute gout attacks // Arthritis & Rheumatism, 2004; 50 (suppl. 9): S339.

Pak C. Y., Peterson R. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate // Arch. Intern. Med., 1986; 146 (5): 863–867.

Singh J. A., Hodges J. S., Toscano J. P. et al. Quality of care for gout in the US needs improvement // Arthritis Rheum., 2007; 57: 822–829.

Slesinger N. Management of acute and chronic gouty arthritis // Drugs, 2004; 64 (21): 2399–2416.

Tsunoda S., Kamide K., Minami J. et al. Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: Effects of a low-energy diet and an insulin-sensitizing agent // Am. J. Hypertens, 2002; 15: 697–701.

Wurzner G., Gerster J. C., Chiolero A. et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout // J. Hypertens, 2001; 19: 1855–1860.

Wyngaarden J. B., Kelley W. N. (eds). Gout and Hyperuricemia. London: Grune & Stratton, 1976: 233–52.

Zhang W., Doherty M., Bardin T. et al. Clinical Studies Including Therapeutics (ESCISIT) EULAR Standing Committee For International Part II: Management. Report of a task force of the EULAR evidence based recommendations for gout // Ann. Rheum. Dis., 2006; 65: 1312–1324.

Zhang W., Doherty M., Pascual-Gуmez E. et al. EULAR evidence based recommendation for the diagnosis and management of gout // Ann. Rheum. Dis., 2005; 64 (suppl. 3): 501.